8-K: Aethlon Medical Amends Warrants for Immediate Exercise

Aethlon Medical, Inc. amended agreements with an institutional investor, removing the shareholder approval requirement for pre-funded warrants, making them immediately exercisable.

Summary

• Aethlon Medical, Inc. (the Company) and an institutional investor (the Purchaser) entered into an Amendment to Securities Purchase Agreement (the SPA Amendment) and an Amendment to Pre-Funded Common Stock Purchase Warrant (the PFW Amendment) on January 22, 2026.
• The SPA Amendment and PFW Amendment modify the terms of the original Securities Purchase Agreement dated December 5, 2025, and the Pre-Funded Common Stock Purchase Warrant dated December 8, 2025.
• The key change is the removal of the requirement for the Company to obtain shareholder approval under Nasdaq Rule 5635 prior to the pre-funded warrants becoming exercisable.
• As a direct result of these amendments, the pre-funded warrants held by the institutional investor are now immediately exercisable.
• All other terms and conditions of the original Securities Purchase Agreement and Pre-Funded Common Stock Purchase Warrant remain unchanged.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the immediate exercisability of warrants could provide faster access to capital for the company, the removal of shareholder approval for such an event might be viewed with caution by some investors regarding corporate governance and potential dilution.

Positives

• The immediate exercisability of pre-funded warrants provides the Company with increased flexibility to potentially access capital more quickly if the investor chooses to exercise them.
• Streamlines the financing process by removing a potential administrative hurdle (shareholder approval) for warrant exercise.

Negatives

• The removal of the shareholder approval requirement for warrant exercise bypasses a layer of corporate governance that typically provides oversight on potential dilution events.
• Immediate exercisability could lead to faster dilution for existing shareholders if the warrants are exercised, potentially impacting share price.

Risks

• Potential dilution of existing shareholders' equity if the pre-funded warrants are exercised, increasing the number of outstanding common shares.
• Impact on the Company's stock price due to the increased supply of shares upon warrant exercise.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the immediate exercisability of the pre-funded warrants, which implies a potential future capital infusion upon exercise.

Management Comments

• James B. Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical, Inc., signed the amendments on behalf of the Company.

Industry Context

This type of amendment is a common financial maneuver in the biotechnology or medical device industry, where companies often rely on structured financing agreements, including warrants, to raise capital. Adjusting terms to facilitate immediate exercisability can be driven by a need for faster access to funds or to simplify the capital structure for investors. The involvement of institutional investors like Armistice Capital, LLC is typical for such financing arrangements.

Comparison to Industry Standards

• The use of pre-funded warrants as part of a financing package is a standard practice in the small-cap and growth-oriented sectors, particularly in biotech, to raise capital while managing immediate dilution and offering investors a structured entry point.
• The removal of shareholder approval for warrant exercise, while permissible under certain Nasdaq rules (like 5635, which was referenced), can be viewed differently across the industry. Some companies prioritize shareholder input for significant dilution events, while others opt for more streamlined processes to expedite financing.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential immediate dilution if the pre-funded warrants are exercised, as the shareholder approval step has been removed. However, the company could receive capital from such exercises.
• Company: Gains increased flexibility and potentially faster access to capital through the immediate exercisability of the pre-funded warrants.

Next Steps

• The institutional investor now has the immediate ability to exercise the pre-funded warrants, which could result in an increase in the Company's outstanding shares and capital.

Key Dates

Recommendation

This filing details a technical amendment to existing financing agreements, making pre-funded warrants immediately exercisable by an institutional investor. While this could facilitate capital infusion for the company, it also introduces immediate potential for dilution without direct shareholder consent on the timing of exercise. This is a structural financing adjustment rather than an operational update, warranting a neutral 'hold' stance until further financial or operational details emerge regarding the company's performance or the actual exercise of these warrants.

Keywords

Aethlon Medical, AEMD, Warrants, Pre-Funded Warrants, Securities Purchase Agreement, Financing, Capital Raise, Nasdaq, Shareholder Approval, Dilution